posted on 2019-02-27, 00:00authored byClaudia Llinas del Torrent, Nil Casajuana-Martin, Leonardo Pardo, Gary Tresadern, Laura Pérez-Benito
The metabotropic
glutamate 5 (mGlu5) receptor is a class
C G protein-coupled receptor (GPCR) that is implicated in several
CNS disorders making it a popular drug discovery target. Years of
research have revealed allosteric mGlu5 ligands showing
an unexpected complete switch in functional activity despite only
small changes in their chemical structure, resulting in positive allosteric
modulators (PAM) or negative allosteric modulators (NAM) for the same
scaffold. Up to now, the origins of this effect are not understood,
causing difficulties in a drug discovery context. In this work, experimental
data was gathered and analyzed alongside docking and Molecular Dynamics
(MD) calculations for three sets of PAM and NAM pairs. The results
consistently show the role of specific interactions formed between
ligand substituents and amino acid side chains that block or promote
local movements associated with receptor activation. The work provides
an explanation for how such small structural changes lead to remarkable
differences in functional activity. While this work can greatly help
drug discovery programs avoid these switches, it also provides valuable
insight into the mechanisms of class C GPCR allosteric activation.
Furthermore, the approach shows the value of applying MD to understand
functional activity in drug design programs, even for such close structural
analogues.